Chronic Rhinosinusitis With Nasal Polyps

10
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
3
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 7 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
4 programs
3
1
Dupilumab SAR231893Phase 4
ItepekimabPhase 3Monoclonal Antibody
ItepekimabPhase 3Monoclonal Antibody
ItepekimabPhase 3Monoclonal Antibody
Sanofi
SanofiPARIS, France
2 programs
1
1
Dupilumab SAR231893Phase 41 trial
lunsekimigPhase 21 trial
Active Trials
NCT06914908Recruiting64Est. Jan 2031
NCT05049122Completed25Est. Jul 2023
CT
1 program
1
210mg of TQC2731 injectionPhase 21 trial
Active Trials
NCT06451640CompletedEst. Oct 2025
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
1
CBP-201Phase 21 trial
Active Trials
NCT04783389TerminatedEst. Jun 2022
Upstream Bio
Upstream BioWALTHAM, MA
1 program
1
VerekitugPhase 21 trial
Active Trials
NCT06164704CompletedEst. Jul 2025
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 282Phase 11 trial
Active Trials
NCT02170337Completed41Est. May 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SanofiDupilumab SAR231893
Sanofilunsekimig
Chia Tai TianQing Pharmaceutical Group210mg of TQC2731 injection
Upstream BioVerekitug
Connect BiopharmaCBP-201
AmgenAMG 282

Clinical Trials (6)

Total enrollment: 130 patients across 6 trials

NCT05049122SanofiDupilumab SAR231893

Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)

Start: Oct 2021Est. completion: Jul 202325 patients
Phase 4Completed
NCT06914908Sanofilunsekimig

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

Start: May 2025Est. completion: Jan 203164 patients
Phase 2Recruiting
NCT06451640Chia Tai TianQing Pharmaceutical Group210mg of TQC2731 injection

A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

Start: Jul 2024Est. completion: Oct 2025
Phase 2Completed
NCT06164704Upstream BioVerekitug

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Start: Dec 2023Est. completion: Jul 2025
Phase 2Completed
NCT04783389Connect BiopharmaCBP-201

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Start: Jun 2021Est. completion: Jun 2022
Phase 2Terminated
NCT02170337AmgenAMG 282

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Start: Jul 2014Est. completion: May 201641 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 130 patients
7 companies competing in this space